Results 221 to 230 of about 16,340 (253)

Radioembolization for hepatic metastases

Seminars in Oncology, 2002
In a phase I/II study, 37 patients with metastatic liver disease, predominantly from colorectal cancer (n = 33) were treated between 1986 and 1994 by intrahepatic arterial embolization of radioactive yttrium 90 (Y 90) glass microspheres. The calculated total liver dose increased in stages from 5,000 cGy to 15,000 cGy. Mean follow-up was 8 months (range,
Milton J, Herba, Michael P, Thirlwell
openaire   +2 more sources

Transarterial yrittrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.

Journal of Vascular and Interventional Radiology, 2022
PURPOSE To investigate the overall efficacy and survival profile of Yrittrium-90 (Y-90) radioembolization for unresectable intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS A systematic literature review and meta-analysis was completed using
D. Schartz, M. Porter, E. Schartz, J. Kallas, Akshya Gupta, D. Butani, A. Cantos   +6 more
semanticscholar   +1 more source

Survival and Toxicities after 90Y Transarterial Radioembolization of Metastatic Colorectal Cancer in the RESIN Registry.

Radiology, 2022
Background Patients with unresectable, chemorefractory hepatic metastases from colorectal cancer have considerable mortality. The role of transarterial radioembolization (TARE) with yttrium 90 (90Y) microspheres is not defined because most reports are ...
E. Emmons, Steven Bishay, Liping Du, H. Krebs, R. Gandhi, Z. Collins, R. O'Hara, N. Akhter, E. Wang, C. Grilli, J. Brower, Shannon R Peck, M. Petroziello, A. A. Abdel Aal, J. Golzarian, A. Kennedy, L. Matsuoka, D. Sze, Daniel B. Brown   +18 more
semanticscholar   +1 more source

Radioembolization for Cholangiocarcinoma

Digestive Disease Interventions, 2021
AbstractCholangiocarcinoma is the second most common primary hepatic malignancy which accounts for 13% of total cancer mortality worldwide. Surgical resection is the only curative treatment for localized disease; however, the majority of patients present when the tumor is unresectable.
Aamir Ali, Komal Manzoor, Jeffrey L. Weinstein, Salomao Faintuch, Muneeb Ahmed, Ammar Sarwar   +5 more
openaire   +1 more source

Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review.

Radiographics, 2021
Transarterial radioembolization (TARE) with yttrium 90 has increasingly been performed to treat hepatocellular carcinoma (HCC). TARE was historically used as a palliative lobar therapy for patients with advanced HCC beyond surgical options, ablation, or ...
F. Miller, Camila Lopes Vendrami, A. Gabr, J. Horowitz, Linda C Kelahan, A. Riaz, R. Salem, R. Lewandowski   +7 more
semanticscholar   +1 more source

Radioembolization plus Immune Checkpoint Inhibitor Therapy compared to Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma.

Journal of Vascular and Interventional Radiology
PURPOSE To investigate if combination therapy with immune checkpoint inhibitor (ICI) and Y90 radioembolization results in superior outcomes than tyrosine kinase inhibitor (TKI) therapy and Y90 for the treatment of intermediate-to-advanced stage ...
K. Garcia-Reyes, Ricki A. Gottlieb, Kartikeya M. Menon, V. Bishay, Rahul S. Patel, Rajesh Patel, S. Nowakowski, Max W. Sung, T. Marron, William H. Gansa, Jack Y Zhang, S. Raja, D. Shilo, A. Fischman, R. Lookstein, Edward Kim   +15 more
semanticscholar   +1 more source

Radioembolization in liver tumors

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2019
The detection of malignant liver tumours is recently increasing. These lesions have frequently arterial vascularization which differs from healthy parenchyma with main portal flow making them especially susceptible to transarterial therapies. Transarterial Radioembolization (TARE) is an emerging treatment for the management of different liver tumours ...
L, Carrion-Martin, J, Orcajo Rincón, A, Rotger, M, Gonzalez-Leyte, L, Márquez Pérez, M, Echenagusia, A, Matilla   +6 more
openaire   +2 more sources

Radioembolization Dosimetry: The Road Ahead

CardioVascular and Interventional Radiology, 2014
Methods for calculating the activity to be administered during yttrium-90 radioembolization (RE) are largely based on empirical toxicity and efficacy analyses, rather than dosimetry. At the same time, it is recognized that treatment planning based on proper dosimetry is of vital importance for the optimization of the results of RE.
Smits, Maarten L J, Elschot, Mattijs, Sze, Daniel Y, Kao, Yung H, Nijsen, JFW, Iagaru, Andre H, de Jong, Hugo W A M, van den Bosch, Maurice A A J, Lam, Marnix G E H   +8 more
openaire   +3 more sources

Chemoembolization and radioembolization

Best Practice & Research Clinical Gastroenterology, 2014
Chemoembolization and radioembolization are at the core of the treatment of patients with hepatocellular carcinoma who cannot receive potentially curative therapies such as transplantation, resection or percutaneous ablation. They differ in the mechanism of action (ischaemia and increase cytotoxic drug exposure for chemoembolization, internal ...
openaire   +2 more sources

Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐Year Experience in 207‐Patient Cohort

Hepatology, 2020
Radioembolization (yttrium‐90 [Y90]) is used in hepatocellular carcinoma (HCC) as a bridging as well as downstaging liver‐directed therapy to curative liver transplantation (LT). In this study, we report long‐term outcomes of LT for patients with HCC who
A. Gabr, L. Kulik, S. Mouli, A. Riaz, R. Ali, K. Desai, R. Mora, D. Ganger, Haripriya Maddur, S. Flamm, J. Boike, Christopher Moore, B. Thornburg, Ali Alasadi, Talia B. Baker, D. Borja-Cacho, N. Katariya, D. Ladner, J. Caicedo, R. Lewandowski, R. Salem   +20 more
semanticscholar   +1 more source